… Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

… An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA)
as a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

… Our research focuses in the elucidation of the nature of circulating cell-free DNA (ccfDNA) …
Working on breast cancer, it became clear that although a promising biosource, its clinical …

… Currently, decision making for ACT treatment is based on risk stratification by stage and
clinical risk factors. We found that in multivariate analysis ctDNA status (among stage, CEA, and …

… data on the use of ctDNA in cancer patients is promising, it is … help guide clinical management
of cancer patients during the … for early cancer detection also examine cell-free DNA (cfDNA…

… Dying cells release their DNA into blood plasma, where it is fragmented by nucleases into
cell-free DNA (cfDNA). cfDNA consists of short (≈160 nt) double-stranded DNA fragments that …

… an additional preservative to reduce cellular DNA release [68]. Comparative studies … cell-free
DNA™ tubes outperform conventional EDTA tubes at preventing significant genomic DNA …

… more useful tests for monitoring treatment response and to inform clinical decision making.
The purpose of this study was to compare circulating cell-free DNA (cfDNA) and circulating …

… introducing the concept of cell-free DNA (cfDNA) and … role in detecting early lesions and
distinguishing benign from malignant lesions. We will finally discuss its potential role in cancer …

… The inability to identify risk of recurrence—beyond conventional surgical staging—complicates
adjuvant treatment decision making and potentially impairs patient survival. Some …